Jefferies Group’s Eledon Pharmaceuticals ELDN Stock Holding History

Jefferies Group’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-2	Closed	-$5K	–	2475
2015 Q2	$5K	Buy	+2	New	+$3.87K	﹤0.01%	2985

Other funds holding ELDN

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jefferies Group's ELDN Position: Q3 2015 in Review

Jefferies Group sold out of Eledon Pharmaceuticals (ELDN) in Q3 2015, closing a stake of 2 shares — an estimated $5K sold.

Jefferies Group first reported a position in ELDN in Q2 2015 and held it in 1 quarter. The position peaked at $5K in Q2 2015. 49 funds tracked by Wall St. Rank hold ELDN as of Q3 2015.

Jefferies Group reported no remaining Eledon Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Jefferies Group sold 2 Eledon Pharmaceuticals shares in Q3 2015, an estimated $5K.
Jefferies Group first reported a position in Eledon Pharmaceuticals in Q2 2015 and held it in 1 quarter.
Jefferies Group's Eledon Pharmaceuticals position peaked at $5K in Q2 2015.
49 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2015.

Based on Jefferies Group's 13F filing for Q3 2015, filed 13 Nov 2015.